Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and...
Shares of Compugen Ltd. (NASDAQ:CGEN – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 […]
Autolus Therapeutics (NASDAQ:AUTL – Get Rating) and Compugen (NASDAQ:CGEN – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Insider & Institutional Ownership 66.6% of Autolus Therapeutics shares are […]
NeuroSense entered into a securities purchase agreement with a single health-care focused investor for 3,000,000 ordinary shares
Study builds on clinical benefit reported in heavily pretreated platinum resistant ovarian cancer patients treated with dual and triple combination of COM701 + nivolumab ± BMS-986207Initial findings expected by the end of 2023HOLON, ISRAEL, June ...